全文获取类型
收费全文 | 993322篇 |
免费 | 71685篇 |
国内免费 | 1577篇 |
学科分类
医药卫生 | 1066584篇 |
出版年
2019年 | 7312篇 |
2018年 | 10553篇 |
2017年 | 8219篇 |
2016年 | 8953篇 |
2015年 | 10205篇 |
2014年 | 14067篇 |
2013年 | 20405篇 |
2012年 | 28472篇 |
2011年 | 29642篇 |
2010年 | 17346篇 |
2009年 | 16527篇 |
2008年 | 28664篇 |
2007年 | 30026篇 |
2006年 | 30656篇 |
2005年 | 29597篇 |
2004年 | 28489篇 |
2003年 | 27228篇 |
2002年 | 26560篇 |
2001年 | 55260篇 |
2000年 | 57014篇 |
1999年 | 47564篇 |
1998年 | 11423篇 |
1997年 | 10101篇 |
1996年 | 10140篇 |
1995年 | 9346篇 |
1994年 | 8705篇 |
1993年 | 7948篇 |
1992年 | 35794篇 |
1991年 | 34244篇 |
1990年 | 33005篇 |
1989年 | 32124篇 |
1988年 | 29216篇 |
1987年 | 28481篇 |
1986年 | 26517篇 |
1985年 | 25465篇 |
1984年 | 18205篇 |
1983年 | 15453篇 |
1982年 | 8260篇 |
1979年 | 15953篇 |
1978年 | 10837篇 |
1977年 | 9276篇 |
1976年 | 8053篇 |
1975年 | 8827篇 |
1974年 | 10616篇 |
1973年 | 10030篇 |
1972年 | 9488篇 |
1971年 | 8957篇 |
1970年 | 8496篇 |
1969年 | 8001篇 |
1968年 | 7282篇 |
排序方式: 共有10000条查询结果,搜索用时 750 毫秒
1.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
2.
3.
4.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
5.
6.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
7.
8.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
9.
Brittney H. Cotta Margaret F. Meagher Aaron Bradshaw Stephen T. Ryan Gerant Rivera-Sanfeliz 《Expert review of anticancer therapy》2019,19(4):301-308
Introduction: Percutaneous renal mass biopsy has evolved over the last decade with improvements on previous pitfalls including low tissue yield, high non-diagnostic rates, and complications. As understanding of tumor biology and natural history of renal cortical neoplasms has improved, percutaneous renal mass biopsy is poised to have an expanding role in an area characterized by individualized management and refined risk stratification.
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献
10.